Discriminative value of serum amyloid A and other acute-phase proteins for coronary heart disease

被引:56
作者
Delanghe, JR
Langlois, MR
De Bacquer, D
Mak, R
Capel, P
Van Renterghem, LV
De Backer, G
机构
[1] State Univ Ghent Hosp, Dept Clin Chem Microbiol & Immunol, B-9000 Ghent, Belgium
[2] State Univ Ghent Hosp, Dept Publ Hlth, B-9000 Ghent, Belgium
[3] Free Univ Brussels, Erasme Hosp, Dept Med Chem, B-1050 Brussels, Belgium
关键词
serum amyloid A; C-reactive protein; acute-phase proteins; inflammation; coronary heart disease;
D O I
10.1016/S0021-9150(01)00607-4
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
We studied the value of serum amyloid A (SAA), a first-class acute-phase protein. as a marker for coronary heart disease (CHD) in a middle-aged male population. In a working population of 16 307 men (age. 35-59 years), 446 cases had a history of CHD or prominent Q:QS waves on electrocardiogram. For each case, two thatched controls here investigated. SAA. measured by immunonephelometry, was correlated with other acute-phase proteins, cardiovascular risk factors, and infectious serology markers. SAA concentrations were significantly higher in the cases than in controls (P < 0.05) and correlated with serum C-reactive protein (CRP) (r = 0.61), plasma fibrinogen (r = 0.39). serum haptoglobin (r = 0.36). and body mass index (r = 0.1 3) (P < 0.001). Serum CRP is a better marker for CHD than SAA, which showed discriminative porter only in a univariate model comparing highest versus lowest tertile (odds ratio, 1.39; 95% confidence interval, 1.03-1.87). Neither SAA nor other acute-phase proteins correlated with Chlamydia pneumoniae immunoglobulin (Ig)G, Helicobacter pylori IgG and IgA, and cytomegalovirus IgG. In conclusion, although SAA has a discriminative value for CHD, serum CRP is to be preferred as a first-class acute-phase reactant for detection of the disease. (C) 2002 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:471 / 476
页数:6
相关论文
共 33 条
  • [21] The first international standard for serum amyloid A protein (SAA). Evaluation in an international collaborative study
    Poole, S
    Walker, D
    Das, REG
    Gallimore, JR
    Pepys, MB
    [J]. JOURNAL OF IMMUNOLOGICAL METHODS, 1998, 214 (1-2) : 1 - 10
  • [22] RIDKER P, 1997, NEW ENGL J MED, V337, P973
  • [23] Ridker P M, 1999, Blood Coagul Fibrinolysis, V10 Suppl 1, pS9
  • [24] Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels
    Ridker, PM
    Rifai, N
    Pfeffer, MA
    Sacks, FM
    Moye, LA
    Goldman, S
    Flaker, GC
    Braunwald, E
    [J]. CIRCULATION, 1998, 98 (09) : 839 - 844
  • [25] C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women
    Ridker, PM
    Hennekens, CH
    Buring, JE
    Rifai, N
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2000, 342 (12) : 836 - 843
  • [26] Rifai N, 1999, CLIN CHEM, V45, P1967
  • [27] Rifai N, 1999, CLIN CHEM, V45, P2136
  • [28] Mechanisms of disease - Atherosclerosis - An inflammatory disease
    Ross, R
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1999, 340 (02) : 115 - 126
  • [29] METHOD FOR THE DETERMINATION OF FUNCTIONAL (CLOTTABLE) FIBRINOGEN BY THE NEW FAMILY OF ACL COAGULOMETERS
    ROSSI, E
    MONDONICO, P
    LOMBARDI, A
    PREDA, L
    [J]. THROMBOSIS RESEARCH, 1988, 52 (05) : 453 - 468
  • [30] Troch T. T., 1999, Clinical Chemistry and Laboratory Medicine, V37, pS88